Bayer AG is a German multinational pharmaceutical and biotechnology company headquartered in Leverkusen, Germany. Founded in 1863, it is one of the world's largest pharmaceutical and biomedical companies.
Biocon's Yesafili, an interchangeable aflibercept biosimilar, is now available in the U.S., while Zydus Lifesciences launched Anyra in India. Both aim to treat retinal diseases such as diabetic macular edema. Biocon plans further launches in the UK and other markets, as competition intensifies.
U.S. biotech IPOs have returned 55% on average this year, crushing the broader IPO market. Nvidia exited Recursion as ARK Invest bought shares, while Revolution Medicines gained 132% on strong pancreatic cancer data.
AI is transforming cardiovascular medicine: $1.4B+ in investments, a new cardiac biomarker sensor, and stroke-imaging software in 2,500+ hospitals. FDA, EMA, and PMDA are opening clearer regulatory pathways.
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
Africa launched its first AI-driven biomanufacturing facility to generate over one million clinico-genomic insights, while India is advancing a BioAI initiative under the Bio-E3 policy to integrate AI with genomics for precision medicine and sustainable biomanufacturing.
Bayer’s sevabertinib has obtained domestic approval as an imported rare drug for HER2-mutant non-small cell lung cancer. The oral reversible HER2-targeted TKI was previously approved by the FDA for previously treated patients.
Pharmaceutical companies are delaying European drug launches due to uncertainty over U.S. pricing policies under President Trump. New drug launches in EU markets fell 35% following Trump's executive order on international reference pricing. Companies fear lower European prices could undermine their ability to maintain higher prices in the $700 billion U.S. market.
Bayer achieved its upgraded 2025 financial targets with group sales reaching 45.6 billion euros and projects solid 2026 performance. The company's pharmaceutical business shows rejuvenation with launch medicines becoming growth drivers, while Crop Science progresses in profitability improvement. Bayer continues strategic diversification in oncology and addresses litigation challenges while implementing cost-saving measures.
Bayer's Phase III FIND-CKD trial shows finerenone significantly slows kidney function decline in non-diabetic chronic kidney disease patients. The drug met its primary endpoint with improved eGFR slope over 32 months, marking its fifth consecutive positive Phase III trial. Bayer plans to submit the data to the FDA for label expansion into non-diabetic CKD.
Zydus Lifesciences launched ANYRA, India's first indigenously developed aflibercept biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer for multiple ophthalmic indications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07762287 |
Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants |
RECRUITING | PHASE1 |
| NCT07753252 |
Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body |
NOT_YET_RECRUITING | PHASE1 |
| NCT07752732 |
Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR) |
RECRUITING | |
| NCT07730151 |
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07723248 |
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) |
RECRUITING | PHASE3 |
| NCT07722585 |
A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the Body |
RECRUITING | PHASE1 |
| NCT07717099 |
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07715279 |
Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression |
NOT_YET_RECRUITING | PHASE2 |
| NCT07677566 |
177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial |
NOT_YET_RECRUITING | PHASE4 |
| NCT07672119 |
A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide |
RECRUITING |
